Citizens JMP Reiterates Market Outperform Rating on Summit Therapeutics plc (SMMT)

Citizens JMP analyst Reni Benjamin reiterated a Market Outperform rating and $40.00 price target on Summit Therapeutics plc (NASDAQ: SMMT).

The analyst commented, "• We reiterate our Market Outperform rating and $40 price target for Summit Therapeutics based on a discounted earnings per share and revenue multiple analysis. Recently, Summit reported 2Q25 earnings and provided corporate updates, including that HARMONi-3 and HARMONi-7 Phase 3 trials have begun enrolling patients. With longer follow-up, HARMONi top-line results expected at WCLC 2025, potential HARMONi-2 OS data by YE25/early 2026 (Akeso's timeline [9926.HK, NC]), multiple Phase 3 trials ongoing, an accomplished team at the helm, and a strong cash position of $297.9MM, we continue to view Summit shares as an attractive investment opportunity, with ~36% downside ($17 bear case) and ~75% upside ($46 bull case)."

For an analyst ratings summary and ratings history on Summit Therapeutics plc click here. For more ratings news on Summit Therapeutics plc click here.

Shares of Summit Therapeutics plc closed at $26.29 yesterday.

You May Also Be Interested In

• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Jefferies on Five Below (FIVE): 'Our latest channel checks reinforce our view that FIVE's momentum extends well beyond viral Squish trends'
• Mosaic sets pricing for tender offers on up to $1.4B in debt